Induced nuclear reactions: processes – systems – and elements – Nuclear transmutation – By neutron bombardment
Reexamination Certificate
1998-09-11
2001-04-24
Carone, Michael J. (Department: 3641)
Induced nuclear reactions: processes, systems, and elements
Nuclear transmutation
By neutron bombardment
C376S189000
Reexamination Certificate
active
06222896
ABSTRACT:
BACKGROUND OF THE INVENTION
For a number of years, isotopes of rhenium, particularly
186
Re and
188
Re, have been of interest to the nuclear medicine community for use in therapeutic applications. Both
186
Re and
188
Re are beta-emitting radionuclides with relatively short half lives of 90 hours and 17 hours, respectively. The maximum beta energy of
186
Re is 1.07 MeV, while that of
188
Re is 2.12 MeV. In addition, both isotopes exhibit gamma emissions (9.2%, 137 keV and 15%, 155 keV, respectively) suitable for evaluation of in vivo distribution of rhenium agents. Recent measurements of
186
Re by the National Institute of Standards and Technology (Coursey et al., Appl. Radiat. Isot. Vol. 42, No. 9, 865, 1991) showed that the decay half-life of
186
Re is 89.25+/−0.07 hours and that the probability of emission of the principal gamma ray at 137 keV was 0.0945+/−0.0016. The beta emission at 1.077 MeV is 71.4% abundant, the emission at 0.94 MeV contributes 21.3%, and 7.28% by electron capture.
Major areas of interest for
186
Re and
188
Re include: radiolabeled monoclonal antibodies (Su et al., J. Nucl. Med. Abstr. 484 31, 823, 1990; DiZio et al., Bioconjugate Chem 2, 353, 1991; Weiden et al., Radiopharm 5, 141, 1992); lung and colon carcinomas (Schroff et al., Immunoconjugates Radio-pharmaceuticals 3, 99, 1990); labeled progestin conjugates for possible treatment of steroid receptor-positive tumors (DiZio et al., J. Nucl. Med. Vol. 33, No. 4, 558, 1992); labeled phosphonate complexes (
186
Re-HEDP) for relief of pain associated with metastatic bone cancer (Pipes et al., J. Nucl. Med. Abstr. 254, 31, 768, 1990); and labeled dimercaptosuccininic acid (
186
Re-DMSA) for tumors of the head and neck (Bisunadan et al., Appl. Radiat. Isot. 42, 167, 1991). Recently, Ehrhardt et al. evaluated the formulation of
186
Re labeled human serum albumin microspheres in an animal model as a potential radiation synovectomy agent Rhenium-186 labeled hydroxyapatite particles are also being evaluated as a potential radiopharmaceutical for radiation synovectomy (Chinol et al., J. Nucl. Med., 34: 1536, 1993; Clunie et al., Nucl. Med., 36: 51, 1995).
186
Re and
188
Re can be produced via a (n,&ggr;) reaction from
185
Re and
187
Re target nuclides, respectively. According to one approach, a
185
Re target nuclide—present either as a thick metal target of isotopically enriched elemental
185
Re (95%) or as a water soluble perrhenate salt (e.g. aluminum perrhenate, Al(
185
ReO
4
)
3
)—is irradiated with thermal neutrons at a flux of about 10
13
-10
15
n/cm
2
s to form a product
186
Re nuclide. When a elemental rhenium target is employed, the product nuclide is recovered by oxidizing the rhenium metal with an oxidizing solvent such as H
2
O
2
or nitric acid to obtain a soluble perrhenate solution which includes the product nuclide. When a perrhenate salt target is employed, the product nuclide is recovered by dissolving the irradiated perrhenate target in water or saline solution (Ehrhardt et al., U.S. Pat. No. 5,053,186). However, it would be beneficial to improve the specific activity of the
186
Re formed via such conventional (n,&ggr;) approaches. Although the thermal and epithermal neutron cross-sections for Re-185 are high (106 b and 1632 b, respectively), the specific activity of
186
Re produced using conventional (not) methods in a reactor such as the Missouri University Research Reactor, MURR, with a thermal neutron flux 4.5×10
14
n/cm
2
s, is only about 3 Ci/mg Re. Since only a handful of reactors with higher neutron fluxes are operating in the world, using a higher neutron flux to enhance the specific activity of
186
Re is not a viable commercial alternative.
Another approach for producing
186
Re and
188
Re via a (n,&ggr;) reaction involves the use of a Szilard-Chalmers reaction, in which the chemical and/or physical changes to a nuclide that result from a neutron-capture reaction are employed advantageously. The study of the chemical, behavior of high energy atoms produced from nuclear reactions and/or radioactive decay processes, typically referred to as “hot atom” chemistry, was initiated in 1934 by L. Szilard and T. A. Chalmers, who demonstrated that after ethyl iodide was irradiated by thermal neutrons, some of the radioactive I-128 could be extracted from the ethyl iodide by water. (Szilard and Chalmers, Nature, 134, 462, 1934). According to most known Szilard-Chalmers techniques for producing
186
Re and/or
188
Re, an organic-Re complex is used as the starting material, and the ~6 MeV of excitation gamma energy emitted by the rhenium nucleus after thermal neutron capture (ie., recoil energy) ruptures the organometallic bonds. Schubiger et al. (Technical University of Munich, Munich, Germany, 1995) reported irradiating a rhenium compound, Cp*ReO
3
(pentamethyl cyclopentadienyl rheniumtrioxide), and observed that the activated compounds containing hot Re atoms decomposed to water soluble perrhenate while the rest of the molecules would remain in the organic phase. The specific activity of
186
Re was, in this case, reported as being enhanced by a factor between 400-800 with neutron irradiation at 1.5×10
13
n/cm
2
s for 10 minutes. Zhang et al. reported a similar approach. (Zhang et al., Abstracts of Papers, Part I, 212th ACS National Meeting of the American Chemical Society, 1996). However, Szilard-Chalmers reactions normally do not result in significant specific activity enhancement in high neutron fluxes during longer periods of irradiation due to the increased radioactive (gamma and fast-neutron) decomposition of non-activated metal-organic bonds. In other words, experiments using organic compounds frequently produce large enhancement of specific activity for short irradiations in low neutron fluxes, but progressively fail to deliver enhanced specific activity product as irradiation time and neutron flux are increased.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to produce
186
Re,
188
Re and other pharmaceutically useful radionuclides in commercially significant yields and at clinically significant specific activities. It is also an object of the invention to produce such radionuclides using methods and reagents which are commercially attractive.
Briefly, therefore, the present invention is directed to a method for producing a radionuclide via a (n,&ggr;) Szilard-Chalmers reaction. The method generally comprises irradiating a target with neutrons in the presence of an oxidizing agent to form an irradiated mixture. The target comprises a metal target nuclide, such as a rhenium nuclide, in the form of a metallic element or an inorganic metallic compound or salt. The resulting irradiated mixture comprises (a) an oxidized product nuclide formed by reaction of the target nuclide with neutrons via a (n,&ggr;) reaction and with the oxidizing agent via an oxidation reaction, and (b) unreacted target nuclide which has not reacted with a neutron or with the oxidizing agent. The irradiated mixture may also include, but preferably to a minimal extent, target nuclide which has not reacted with a neutron, but which has, nonetheless, been oxidized. The irradiated mixture is then processed to separate the oxidized product nuclide from unreacted target nuclide. According to one aspect of the method, the rate and/or extent of oxidation of target nuclide which has not reacted with a neutron is controlled in a manner to minimize oxidation of such target nuclide. According to another aspect of the method, the amount of oxidizing agent present during irradiation ranging from a stoichiometric amount to about four times the stoichiometric amount required for the target nuclide to react with the oxidizing agent to form the oxidized product nuclide. According to an additional aspect of the method, the target is irradiated with neutrons at a pressure which is less than atmospheric pressure. According to a further aspect of the method, the target is cooled while the target is being irradiated. According to yet another aspect o
Ehrhardt Gary J.
Jia Wei
Carone Michael J.
Mun Kyongteak K.
Senniger Powers Leavitt & Roedel
The Curators of the University of Missouri
LandOfFree
Production of 186Re, 188Re and other radionuclides via... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of 186Re, 188Re and other radionuclides via..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of 186Re, 188Re and other radionuclides via... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2442252